- Home
- / Petros Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Petros Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.4
2024-10-29
Market Capitalization
$3.7 M
2024-10-29
Revenue
$5.1 M
FY, 2024
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| Revenue | 7.8M | 6.0M | 5.8M | 5.1M | |
| Cost of goods sold | 1.6M | 2.3M | 1.6M | 1.2M | |
| Gross profit | 6.2M | 3.7M | 4.2M | 3.9M | |
| Gross profit margin, % | 61.8% | 76.3% | |||
| General and administrative expense | 15.6M | 12.2M | 9.3M | 8.7M | 4.6M |
| Operating expense total | 24.3M | 23.6M | 17.8M | 21.6M | 4.6M |
| Depreciation and amortization | 6.9M | 5.6M | |||
| EBIT | (18.0M) | (19.9M) | (13.6M) | (17.7M) | (4.6M) |
| EBIT margin, % | -332.4% | -345.8% | |||
| Interest income | 14.2K | 515.3K | 371.8K | ||
| Interest expense | 596.0K | 515.3K | 560.9K | 256.9K | |
| Pre tax profit | (9.0M) | (8.2M) | (14.3M) | (4.5M) | |
| Net Income | (9.0M) | (20.0M) | (8.2M) | (14.3M) | 1.9M |
| EPS | (9.7) | (6.0) | (3.3) | (1.6) |